BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grossberg LB, Papamichael K, Cheifetz AS. Review: emerging drug therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2022. [PMID: 35166398 DOI: 10.1111/apt.16785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Lahat A, Klang E. US supreme court decision: the gastroenterological perspective. Therap Adv Gastroenterol 2022;15:17562848221116935. [PMID: 36035307 DOI: 10.1177/17562848221116935] [Reference Citation Analysis]
2 Li DF, Yang MF, Xu HM, Zhu MZ, Zhang Y, Tian CM, Nie YQ, Wang JY, Liang YJ, Yao J, Wang LS. Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease. J Mater Chem B 2022. [PMID: 35876136 DOI: 10.1039/d2tb01190e] [Reference Citation Analysis]
3 Toskas A, Akbar A. IBD therapeutics: what is in the pipeline? Frontline Gastroenterol 2022;13:e35-43. [DOI: 10.1136/flgastro-2022-102130] [Cited by in F6Publishing: 1] [Reference Citation Analysis]